Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Habenbacher, M; Moser, U; Abaira, A; Tomazic, PV; Kiss, P; Holzmeister, C; Pock, J; Walla, K; Lang, A; Andrianakis, A.
Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps.
Nutrients. 2024; 16(17): 2982
Doi: 10.3390/nu16172982
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Andrianakis Alexandros
- Habenbacher Michael
- Co-Autor*innen der Med Uni Graz
- Holzmeister Clemens
- Kiss Peter
- Lang Angelika
- Moser Ulrich Christian
- Pock Jakob
- Tomazic Peter Valentin
- Walla Katharina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life and often presents therapeutic challenges, with biologics like dupilumab showing promise in managing severe, uncontrolled cases. The aim of this study was to assess the influence of overweight on the effectiveness of dupilumab in patients with uncontrolled CRSwNP. This retrospective study analyzed treatment outcomes of 75 CRSwNP patients receiving dupilumab, categorizing them into underweight/normal-weight (BMI ≤ 24.9 kg/m2) and overweight/obese (BMI ≥ 25 kg/m2) groups. Outcome measures included changes in nasal polyp score (NPS) and sinonasal outcome test (SNOT-22) scores. Results demonstrated that the underweight/normal-weight group experienced significantly greater improvements in NPS and a higher rate of total NPS improvement compared to the overweight/obese group. While SNOT-22 scores improved in both groups, no significant differences were observed. Among patients with comorbid asthma, the underweight/normal-weight subgroup also showed significantly better outcomes, including greater reductions in both NPS and SNOT-22 scores. Multiple regression analysis identified BMI as an independent prognostic factor for NPS outcomes. The findings suggest that overweight/obesity adversely affects the response to dupilumab in CRSwNP, emphasizing the need for personalized treatment strategies considering BMI.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Nasal Polyps - drug therapy, complications
- Male - administration & dosage
- Female - administration & dosage
- Sinusitis - drug therapy, complications
- Antibodies, Monoclonal, Humanized - therapeutic use
- Retrospective Studies - administration & dosage
- Middle Aged - administration & dosage
- Rhinitis - drug therapy, complications
- Chronic Disease - administration & dosage
- Overweight - complications, drug therapy
- Adult - administration & dosage
- Treatment Outcome - administration & dosage
- Body Mass Index - administration & dosage
- Obesity - complications, drug therapy
- Aged - administration & dosage
- Quality of Life - administration & dosage
- Rhinosinusitis - administration & dosage
- Find related publications in this database (Keywords)
- obesity
- overweight
- dupilumab
- biologic
- chronic rhinosinusitis
- CRSwNP